IBA unveiled NEPTIS Perform Duo on October 18, 2026, at the EANM’26 Congress in Vienna, introducing a radiopharmaceutical synthesizer designed to handle both tracer development and routine manufacturing on one module. Announced on October 19, the launch is ORA’s first new product since IBA acquired the business in December 2025.
Key Takeaways
- The module combines tracer development and routine production, tasks that producers often handle on separate systems.
- IBA says reusable development components exceeded 30 uses in internal testing; production uses single-use cassettes.
- The launch expands IBA’s radiochemistry offering following its December 2025 acquisition of ORA.
Table of Contents
- How NEPTIS Perform Duo combines two workflows
- Internal testing supports the consumables claim
- ORA broadens IBA’s production offering
- Conclusion
How NEPTIS Perform Duo combines two workflows
Radiopharmaceutical synthesizers automate the chemical processes that combine a radioisotope with other compounds to make drugs used in diagnostic imaging or therapy. Developing a new positron emission tomography, or PET, tracer can require many trial runs, each potentially consuming a new single-use kit.
IBA’s launch announcement for NEPTIS Perform Duo describes a platform that uses reusable components during development, then single-use cassettes for routine manufacturing. The production configuration supports the same cassettes and chemistries as NEPTIS Perform, including FDG, the most widely used PET tracer.
Keeping both stages on the same system is intended to let teams manufacture the process they developed through one qualification path. The practical aim is to reduce the need to move a tracer process between separate development and production platforms.
| Item | Details |
|---|---|
| Existing NEPTIS range | Perform Duo joins NEPTIS Perform and NEPTIS xSeed. |
| Installed footprint | NEPTIS synthesizers are installed at more than 600 sites in over 50 countries. |
| ORA experience | 20 years in radiochemistry. |
| IBA experience | Four decades in cyclotrons. |
Internal testing supports the consumables claim
IBA said the reusable development components were used more than 30 times in internal testing. The company presents reuse as a way to lower consumable costs, but the announcement did not quantify savings or provide a comparison with a separate-system setup.
Loïk-Maël Nys, president of IBA RadioPharma Solutions, said customers increasingly want to develop and manufacture tracers on the same platform. His description of a simpler, more economical workflow represents the company’s expected customer benefit, rather than a disclosed customer performance result.
ORA broadens IBA’s production offering
The module targets contract manufacturers, commercial radiopharmaceutical producers and radiopharmacy networks. It extends IBA’s offering beyond cyclotrons, which produce medical isotopes, into the chemistry needed to turn those isotopes into dose-ready radiopharmaceuticals.
The launch adds a product to the ORA business acquired in December 2025. IBA did not disclose product pricing, orders or a revenue forecast in the announcement, so the release establishes the product’s capabilities rather than its financial contribution.
Conclusion
NEPTIS Perform Duo brings development and manufacturing onto one platform, adding to IBA’s post-acquisition radiochemistry range. The announcement sets out the technical proposition, but leaves commercial uptake and financial contribution unquantified; no subsequent milestone was specified.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
